GLPwatch
Papers (10410)
Page 143 of 174, ranked by citation count.
- Effect of liraglutide treatment on mitigation of hearing damage induced by multiday repeated high-intensity blasts.
- Semaglutide, lipid-lowering drugs, and NAFLD - Author's reply.
- Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis.
- Morphology-driven zinc oxide biointeractive carriers with biological barrier modulating effects for pulmonary delivery of liraglutide.
- The inhibitor VB-87531 synergizes with tirzepatide and semaglutide for greater weight loss in DIO mice.
- Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art.
- Targeting cardiometabolic risk in type 1 diabetes through incretin physiology.
- Tirzepatide (Zepbound) for obstructive sleep apnea.
- Liraglutide Mitigates Renal Injury in Diabetic Kidney Disease by Suppressing Podocyte Cholesterol Accumulation Through mTOR/VMP1-Regulated Autophagy.
- The construction of long-acting exendin-4 analog and its hypoglycemic effect in diabetic mice.
- NICE approves liraglutide for diabetic patients not achieving glucose control.
- Navigating compounded semaglutide: what health care providers need to know.
- Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
- Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment.
- The Effect of GLP-1 Receptor Agonists on Alanine Aminotransferase and Other Metabolic Parameters in Youths with Obesity: A Systematic Review and Meta-Analysis.
- Liraglutide use in pediatric type 2 familial partial lipodystrophy caused by LMNA mutation: a case report.
- Glycemic control and weight changes in patients with type 2 diabetes intensified to three insulin regimens after therapeutic failure to exenatide.
- The Obesity Drug Revolution: New Frontiers in Pharmacotherapy.
- Comments to the Editor Concerning the Paper Entitled "Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4" Mohamed Abd Elaziz Wassef et al.
- [Efficacy and safety of IdegLira for the intensification of type 2 diabetes treatment].
- The lack of efficacy of tirzepatide in mitigating cisplatin-induced neurotoxicity and cognitive impairment in rats.
- Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed.
- When the Transition Goes Wrong: A Rare Case of Diabetic Ketoalkalosis After Transitioning to Tirzepatide in Insulin-dependent Type 2 Diabetes.
- Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity.
- Holistic View of Tirzepatide's Role in Obesity-Related HFpEF.
- Two Trials of Therapeutics for MASH with Liver Fibrosis.
- Approaching therapy of Alzheimer's disease via the antidiabetic drug liraglutide-a study with streptozotocin intracerebroventricularly treated Wistar rats.
- Effectiveness of Telemedicine Prescribing and a Long-Acting Obesity Medication Behavioral Program: A 24-Week Single-Arm Study.
- The incidence of retinopathy in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness study (GRADE).
- Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.
- Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.
- The nuclear option for insulinomas.
- [Treatment of an obese diabetic].
- Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.
- A Clinical Comprehensive Evaluation of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes Management.
- A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists.
- Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.
- [Therapy of obesity with liraglutide. NN8022-1807 study].
- Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.
- Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07.
- Liraglutide for weight management: benefits and risks.
- Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.
- A comment on tirzepatide versus glucagon-like peptide-1 receptor agonists and heart rate with regard to 'Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis'.
- Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials.
- Weight management medications for chronic use in 37 veterans affairs medical centers-A medication use evaluation.
- Semaglutide Initiation in a Type 2 Diabetes Mellitus, Post-Liver Transplant Patient.
- Liraglutide effect on epicardial fat: Missing the forest for the trees.
- Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors.
- The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers.
- Tirzepatide reverses hypothalamic inflammation, cellular stress, and neuropeptide imbalance in metabolic-menopausal dysfunction.
- Clinical experience with liraglutide.
- MASLD Pharmacotherapy: Current Standards, Emerging Treatments, and Practical Guidance for Indian Physicians.
- Dulaglutide 1.5 mg Significantly Improves Glycemic Control and Lowers LDL-Cholesterol and Body Weight in Romanian Patients with Type 2 Diabetes.
- Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
- Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity.
- Efficacy and safety of dapagliflozin and liraglutide in patients with type 2 diabetes mellitus and newly diagnosed as overweight/obese.
- Weekly journal scan: SURMOUNTing body weight regain with tirzepatide after successful lifestyle intervention.
- WEIGHT LOSS IN A YOUNG PATIENT WITH TYPE 2 DIABETES: CHALLENGES OF DIABETES MANAGEMENT USING ONLINE PROGRAM OF GOOD NUTRITION (CASE REPORT).
- [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]